Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fey, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fey, M. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1161-1162, 2003
© 2003 European Society for Medical Oncology

Original Paper

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of acute myeloblastic leukaemia (AML) in adult patients

M. F. Fey

Institute of Medical Oncology, Inselspital and University of Berne, Berne, Switzerland

The first 10% of the full text of this article appears below.


   Incidence
 
The crude incidence of acute myeloblastic leukaemia (AML) in adults in Europe is 5–8 cases/100 000/year. The mortality is ~4–6 cases/100 000/year.


   Diagnosis
 
The diagnosis of AML requires examination of peripheral blood samples and bone marrow aspirates. Work-up should comprise morphological examination, cytochemistry, immuno-phenotyping and cytogenetic analysis.


   Risk assessment
 
Risk assessment in AML includes the patient’s age, the initial leucocyte count, the AML subtype, karyotype data and medical conditions in the patient’s history that may affect the feasibility of . . . [Full Text of this Article]


   Treatment plan
 
Induction chemotherapy
Consolidation therapy
Therapy of relapsed or refractory patients

   Response evaluation
 

   Follow-up
 

   Note
 

   Literature
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
H. Ludwig
A Foundation for the future
Ann. Onc., January 1, 2005; 16(1): 3 - 3.
[Full Text] [PDF]

Home page
 Ann OncolHome page
H. Ludwig
European Society of Medical Oncology membership survey
Ann. Onc., February 1, 2004; 15(2): 181 - 182.
[Full Text] [PDF]